Future Market Insights has announced the addition of the “Cervical Cancer Treatment Market: Industry Analysis and Opportunity Assessment 2016-2026" report to their offering.

1. sales@futuremarketinsights.com
Global Cervical Cancer
Treatment Market
Share, Global Trends,
Analysis, Research, Report,
Opportunities,
Segmentation and Forecast,
2016-2026
www.futuremarketinsights.comFuture Market Insights

2. Customized
Research
Syndicated
Research
Investment
Research
Social Media
Research
Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting
services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes,
technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends.
We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC.
Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and
Retail.
We have a global presence with delivery centers across India specializing in providing global research reports and country
research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India.
We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for
our client.
Research Capabilities
Subscription Information
 Customized Research
 Syndicated Research
 Investment Research
 Social Media Research
Sector Coverage
 Automotive and Transportation
 Electronics, Semiconductor, and ICT
 Retail and Consumer Products
 Industrial Automation and Equipment
 Chemicals & Materials
 Food and Beverages
 Services and Utilities
 Energy, Mining, Oil, and Gas
For detailed subscription information please contact
Hari. T (Sr. Manager - Global Business Development)
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268
Email: hari.t@futuremarketinsights.com

3. Cervical cancer is caused due to uncontrolled division of abnormal or cancerous cell
growth in cervix region (lower uterus part) that leads to vagina in female reproductive
tract. Cervical cancer occurs in sexually active women and is clinically defined by
unpleasant or foul vaginal discharge, pain in pelvis, vaginal pain and bleeding during sex.
99% of cervical cancer cases, over the globe are prevalent due to Sexually Transmitted
Infection (STI) of Human Papiloma Virus (HPV) from an infected individual. HPV infection
brings about DNA mutation in cervical cells (glandular and squamous cells) that alter cell
growth resulting into uncontrolled cell growth to form tumours. Worldwide out of 100
known genotypes of HPV about 13 high risk HPV types leads to cervical cancer while
there is strongest association between infection and invasive cervical cancer for type
HPV-16 and HPV-18 causing 70% of total cervical cancer cases. While other important
cause for cervical cancer other than HPV is exposure to DES (diethylstilbestrol) drug while
being in womb.
The most efficient test for detection of cervical cancer is Pap Smear test while other test
include HPV test, Endocervical curettage, Colposcopy, and Biopsy. The early detection of
precancerous cells and proper treatment can help prevent its progression into cervical
cancer. According to AJCC (American Joint Committee on Cancer) the treatment of
cervical cancer depends upon the stage of cancer which is defined by the size, depth and
metastasis, thus diagnosis of cervical cancer stage plays most important role in treatment
of cervical cancer. Common methods of treatment for early stage cancer include surgery
or radiation therapy combined with chemotherapy while radiation therapy,
Report DescriptionReport Description

4. chemotherapy and hormone therapy often in combination is used in treatment of
advanced cervical cancer stages.
Request Free Report Sample@
http://www.futuremarketinsights.com/reports/sample/rep-gb-1958
Cervical Cancer Treatment Market: Drivers and Restraints
It has been stated by National Cancer Institute that cervical cancer is the fourth most
common cancer and also ranks fourth in high mortality rate in women. It has also been
found that HIV infected women are at such a high risk of cervical cancer that it is denoted
or designated as AIDS defining condition. High prevalence rate, unprotected or unsafe
sex, ignorance of diagnostic test to prevent invasive cancer are major factors in cervical
cancer market drive. While high risk of HPV infection in HIV infected women, more
disease burden in developing or low income countries and availability of advanced and
variety of treatment drives market for cervical cancer treatment.
Whereas in last decade there has been significant growth in prophylactic market in
developed countries and awareness initiative taken by government to educate women
about early diagnostic test and vaccines. This helped in prevention of HPV infection and
also cervical cancer progression into aggressive or advanced stages thus restraining
cervical cancer treatment market. Readily available FDA approved vaccines such as
Gardasil and Cervarix which are much cheaper and readily available than the treatment
brings negative impact on cervical cancer treatment mostly in developed countries.
Report DescriptionReport Description

5. Cervical Cancer Treatment Market: Segmentation
The cervical cancer treatment market is classified on the basis of disease indication, types of
treatment, product type, end user and geography.
Based on disease indication the cervical cancer treatment market is segmented into the
following: (by FIGO- International Federation of Gynecology and Obstetrics),
• Pre-malignant lesions- Cervical Intraepithelial Neoplasia (CIN-1, CIN-2, CIN-3).
• Early invasive stage (IA – IB1 – IIA1).
• Advanced invasive stage (IB2 – IIA2 – IIB – IIIA – IIIB – IVA .
Based on treatment type, the cervical cancer treatment market is segmented into the following:
Cryotherapy.
• Simple hysterectomy.
• Cold knife conization.
• LEEP- Loop electrosurgical excision procedure
• Laser surgery.
• Cone biopsy.
• Radical trachelectomy.
Report DescriptionReport Description

6. • Radiation therapy (Brachytherapy-BT and External beam therapy-EBT).
• Chemotherapy (cisplatin, carboplatin, paclitaxel, doxorubicin, gemcitabine, bevacizumab
etc).
• Targeted therapy (bevacizumab, Pazopanib).
• Hormone therapy (oestrogen, progesterone, progestogens and testosterone).
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1958
Based on end user, the cervical cancer treatment market is segmented into the following:
• Hospitals.
• Cancer Palliative care clinics.
• Diagnostic centers.
• Pharmacies.
Cervical Cancer Treatment Market: Overview
Cervical cancer treatment market holds a larger share as it is one of the most prevalent cancer
amongst women all over the world. American Cancer Society had estimated that there will be
about 12,990 new cases of cervical cancer while 4,120 women would die of cervical cancer in
2016. Increasing prevalence, awareness and advancement in treatment and variety of
treatments available drives market for cervical cancer treatment. Cervical cancer is a well known
secondary infection after HIV (Human Immunodeficiency Virus) infection and HIV infected
Report DescriptionReport Description

7. women are the most high risk population for cervical cancer thus a major risk factor for cervical
cancer. Thus AIDS plays major role in cervical cancer treatment market due to larger population
(50%) without HAART treatment, unprotected or insecured sex practices and government
initiatives for such sexually transmitted diseases. It has been noted that 90% of cervical cancer
cases are incident in developing countries thus being a major market for cervical cancer
treatment.
Cervical Cancer Treatment Market: Regional Overview
Region wise, the global portable ultrasound bladder scanner market is classified into regions
namely, North America, Latin America, Eastern Europe, Western Europe, Japan, Asia-Pacific,
Middle East and Africa. In terms of size North America and Latin America holds highest market
for cervical cancer treatment. Disease burden is more in developing and underdeveloped
countries like China, India and Africa, than in developed countries like America and Europe. But
still the cost for advanced cervical cancer treatment is more in developed countries inspite of
having low or negligible incidence rate for cervical cancer treatment. This is due to such drugs
being under patents used in chemotherapy for cancer treatment in US and Europe that holds
largest market in terms of market share and size. Thus, treatment seen to have been 20 times
expensive than in developing or low income countries. Developing countries show steady
growth in cervical cancer treatment market. Also lack of education, lack of awareness,
inadequate medical facilities and improper market network for cervical cancer treatment in
countries like Africa hinders cervical growth market.
Report DescriptionReport Description

8. Browse Full Report@
http://www.futuremarketinsights.com/reports/cervical-cancer-treatment-market
Cervical Cancer Treatment Market: Key Players
Some of the key players in cervical cancer treatment are Genentech USA, Hetero,
GlaxoSmithKline, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc, Pfizer Inc, ALLERGAN,
Biocon, Bristol-Myers Squibb Company, Novartis Pharmaceuticals Canada Inc, Actavis Pharma
Company.
Report DescriptionReport Description

9. Thank You!
To know more about us, please visit our website:
www.futuremarketinsights.com
For sales queries or new topics email us on:
sales@futuremarketinsights.com
Future Market Insights: 616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
T: +1-347-918-3531 | D: +1-845-579-5705